Role of Intralesional Vitamin D3 in the Treatment of Cutaneous Warts

Cutaneous warts are common benign skin lesions caused by human papillomavirus. Various treatment options are available for these but immunotherapy is becoming more and more popular over the past few years. It stimulates cell-mediated immunity causing clearance of warts. The aim is to determine the r...

Full description

Saved in:
Bibliographic Details
Published inJournal of cutaneous and aesthetic surgery Vol. 14; no. 4; pp. 404 - 408
Main Authors Latif, Insha, Sultan, Javeed, Aslam, Aaqib, Hassan, Iffat, Devi, Reeta
Format Journal Article
LanguageEnglish
Published India Medknow Publications and Media Pvt. Ltd 01.10.2021
Wolters Kluwer - Medknow
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cutaneous warts are common benign skin lesions caused by human papillomavirus. Various treatment options are available for these but immunotherapy is becoming more and more popular over the past few years. It stimulates cell-mediated immunity causing clearance of warts. The aim is to determine the role of intralesional vitamin D3 in the treatment of warts. Consecutive patients with verruca vulgaris attending OPD were included. Around two to three warts were injected first with 0.2 mL of lignocaine (20 mg/mL). After a few minutes, the same warts were injected with 0.2 mL (4 U) of vitamin D3 (15 mg/mL). The injections were given2 weeks apart for a maximum of six sessions, and the patient was followed up 3 months after the last injection. A total of 41 patients of cutaneous warts completed the study. Complete clearance was seen in 27 (65.85%) patients, partial response was seen in 11 (26.83%) patients, and three patients (7.32%) showed no response at all. The mean number of injections required for complete response was four. Recurrence was seen in two patients (4.88%) and one patient had keloid formation at the sight of injection. This is a small sample sized study and lacks a control group. Intralesional vitamin D3 is an effective treatment option for common warts.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0974-2077
0974-5157
DOI:10.4103/JCAS.JCAS_170_20